HEALTHY Study Rationale, Design and Methods: Moderating Risk of Type 2 Diabetes in Multi-Ethnic Middle School Students In this supplement the authors and study group present the rationale and design ...
A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). Design and rationale of a phase 1 dose-escalation ...
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy Case reports and small prospective trials suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results